Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for HTGC and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for HTGC and 80,000+ other tickers.
See exactly how HTGC's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for HTGC and 80,000+ other tickers.
Hercules Capital, Inc. is a business development company. The firm specializing in providing private equity, venture debt, and growth capital to privately held venture capital-backed companies at all stages of development from mid venture to expansion stage including select publicly listed companies and select special opportunity companies that require additional capital to fund acquisitions, recapitalizations and refinancing and established-stage companies. The firm provides growth capital financing solutions for capital extension; management buy-out and corporate spin-out financing…
Hercules Capital's 41.6% biotech and healthcare exposure should benefit from improving sector funding, IPO activity, and M&A exits. Higher interest rates would increase HTGC's net investment income and EPS under its disclosed rate-sensitivity assumptions. HTGC's internal management structure supports a low operating cost ratio and consistently superior ROAA and ROAE versus BDC peers.
Hercules Capital is rated a hold as valuation has rebounded to a 45% premium to book value. HTGC outperformed sector peers with stable NII per share and a 2.1% NAV increase quarter-over-quarter. Credit quality improved year-over-year, with a notable 600 bps rise in Grade 1-rated investments.
Hercules Capital remains a 'Strong Buy' for high-income and total return, supported by a robust venture-lending platform and efficient internal management. HTGC delivered record Q2 investment income of $149 million, with NII per share up 4.7% YoY and strong dividend coverage at 125%. Portfolio quality remains high, with minimal nonaccruals, improved average portfolio grade, and a conservative 20% loan-to-value ratio.
BlackRock Inc. purchased a new stake in shares of Hercules Capital, Inc. (NYSE: HTGC) in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 924,105 shares of the financial services provider's stock, valued at approximately $14,573,000. BlackRock Inc. owned approximately 0.49% of Hercules
The capital you need to retire on dividends alone swings by millions depending on one number, and chasing the wrong yield can quietly erode everything you built.